November 26, 2018 / 9:48 PM / 17 days ago

Bristol-Myers Squibb says cancer drug combination fails maintenance trial

Nov 26 (Reuters) - Bristol-Myers Squibb Co said on Monday a combination of two of its cancer drugs, being tested as a maintenance therapy, did not meet the main goal of extending the lives of lung cancer patients in a late-stage trial.

The study was testing the company’s immunotherapy drug Opdivo along with its older cancer medicine Yervoy versus a placebo in patients with extensive-stage small cell lung cancer whose disease had not progressed after they received chemotherapy. (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below